Cancers & treatments·Regimen libraryAdjuvant

APT (weekly paclitaxel + trastuzumab)

Checked 2026-09-09

Stage I HER2-positive breast cancer, node-negative, tumour 3 cm or smaller

One cycle

weekly × 12 · about 12 weeks in total

7-day cycle × 12 weekly, then trastuzumab every 3 weeks to 1 year (about 12 weeks)Intravenous

Components

Drug	Dose	Route	Days	Note
Paclitaxel Cytotoxic chemotherapy (taxane)	80 mg/m²	IV	D1
Trastuzumab Monoclonal antibody (anti-HER2)	4 mg/kg loading then 2 mg/kg weekly; 6 mg/kg every 3 weeks after chemotherapy	IV	D1

Cycles

12 weekly, then trastuzumab every 3 weeks to 1 year

7-day cycle

Emetogenicity

Low (10-30%)

G-CSF

Not routine

Notes

7-year disease-free survival 93%; T-DM1 × 17 (ATEMPT) is the alternative.

Used in

HER2-positive breast cancer

Trials

APT (adjuvant paclitaxel-trastuzumab)

Products

Paclitaxel / nab-paclitaxelTrastuzumab

Source

APT, NEJM 2015 (Tolaney)

Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.